Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ceftazidime pentahydrate
Drug ID BADD_D00400
Description Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs).[A232920] β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death.[A232920, A232925, A232930] Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as _Pseudomonas aeruginosa_.[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of bacterial infections.[L32935, L32940]
Indications and Usage Ceftazidime is indicated for the treatment of lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections (including peritonitis), and central nervous system infections (including meningitis) caused by susceptible bacteria.[L32935] Ceftazidime is indicated in combination with [avibactam] to treat infections caused by susceptible Gram-negative organisms, including complicated intra-abdominal infections (cIAI), in conjunction with [metronidazole], and complicated urinary tract infections (cUTI), including pyelonephritis, in patients aged three months and older. This combination is also indicated to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older.[L32940] In all cases, to mitigate the risk of bacterial resistance and preserve clinical efficacy, ceftazidime should only be used for infections that are confirmed or strongly suspected to be caused by susceptible bacterial strains.[L32935, L32940]
Marketing Status approved
ATC Code J01DD02
DrugBank ID DB00438
KEGG ID D00921
MeSH ID D002442
PubChem ID 5362051
TTD Drug ID D0PH5Z
NDC Product Code 0264-3145; 25021-127; 0409-5082; 10402-013; 0409-5084; 0409-5086; 0409-5092; 82608-010; 0409-5093; 25021-128; 44567-235; 0264-3143; 52946-0924; 44567-237; 25021-129; 44567-236
UNII 9M416Z9QNR
Synonyms Ceftazidime | Fortaz | Fortum | Ceftazidime Pentahydrate | LY-139381 | LY 139381 | LY139381 | Tazidime | Ceftazidime Anhydrous | Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))- | GR-20263 | GR 20263 | GR20263
Chemical Information
Molecular Formula C22H32N6O12S2
CAS Registry Number 78439-06-2
SMILES CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O -].O.O.O.O.O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase13.03.04.002--Not Available
Alcohol intolerance14.02.01.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema23.04.01.001; 10.01.05.009; 22.04.02.008--Not Available
Aplastic anaemia01.03.03.002--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Aspartate aminotransferase13.03.04.008--Not Available
Asterixis17.01.06.001; 09.01.03.004--Not Available
Blood alkaline phosphatase13.04.02.010--Not Available
Blood bilirubin increased13.03.04.018--
Blood lactate dehydrogenase13.04.02.009--Not Available
Body temperature increased13.15.01.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cholestasis09.01.01.001--Not Available
Colitis07.08.01.001--
Coma17.02.09.001--Not Available
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Encephalopathy17.13.02.001--
Eosinophilia01.02.04.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Gamma-glutamyltransferase13.03.04.022--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Haemoglobin13.01.05.018--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages